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Background.Thisstudywasundertakentoevaluatetheimpactofprognosticfactorsonthelocoregionalfailure-freesurvivalofearly
breast cancer patients. Methods. In this single-institutional study, 213 breast cancer patients were retrospectively analysed. Fifty-
ﬁve of 213 patients were ≤40 years of age at diagnosis. The impact of patient- or treatment-related factors on the locoregional
failure-free survival was assessed using the Kaplan-Meier method. The simultaneous impact of factors on the locoregional
failure-free survival was assessed using the Cox proportional hazards regression analysis. Results. The median follow-up time
of the censored patients was 22 months (mean 28 months, range 3–92 months). On univariate analysis, statistically signiﬁcant
factors for the locoregional failure-free survival were the age (≤40 versus >40 years), T stage (Tis, T0–2 versus T3-4), molecular
tumor type (luminal A versus luminal B, Her2neu overexpression, or triple negative), and lymphovascular status (LV0 versus
LV1). On multivariate analysis, age and T stage remained statistically signiﬁcant. Conclusions. Being 40 years or younger has
a statistically signiﬁcant independent adverse impact on the locoregional failure-free survival of patients with early breast
cancer.
1.Background
Approximately3.7%–7.5%ofthetotalnumberofbreastcan-
cer patients diagnosed each year in the US [1, 2] and Western
Europe [3–5]a r ey o u n g e rt h a n4 0y e a r s .I nS a u d iA r a b i a ,t h e
proportion of breast cancer patients ≤40 years at diagnosis is
dramatically larger with 25.1% [6].
Multiple retrospective series and subset analyses of larger
randomized trials have shown that young patients with
breast cancer have a poorer prognosis [7–16]c o m p a r e dt o
older age at diagnosis. Breast cancer patients ≤40 years tend
to have more triple-negative and fewer luminal A and B
breast cancers [17–19], tumors of higher grade, more exten-
sive intraductal component, more lymphovascular invasion,
more likely estrogen receptor- (ER-) negative tumors [20–
23], and more often BRCA-1 or -2 germline mutations [13,
24–27]. Although young women do appear to have tumors
with more aggressive biological characteristics, younger age
has been shown in several studies to be an independent
predictor of adverse outcome [18, 20, 22, 28–31]. Several
current consensus guidelines have included age ≤35 years as
an absolute indication for adjuvant systemic chemotherapy
irrespective of other tumor characteristics [32–35]. More
research is needed to optimize the treatment for this patient
group [14, 36, 37]. Detailed data about prognostic factors
and treatment outcome in breast cancer are scarce in Saudi
Arabia and the Middle East. The purpose of this study was to
characterize the breast cancer patients treated with curative2 Journal of Oncology
intend of this tertiary care hospital in Saudi Arabia ≤40 years
of age at diagnosis compared to >40 years, and to assess their
prognosis.
2. Methods
Medical records were retrospectively reviewed of female
breastcancerpatientswhoconsultedSaadSpecialistHospital
between 2004 and 2011. Eligibility criteria for the analysis
were histologically conﬁrmed diagnosis of invasive breast
cancer or cancer in situ, surgical treatment with breast con-
serving surgery or mastectomy with curative intent. Patients
with distant metastases, synchronous, or metachronous
cancer at diagnosis were excluded from the analysis.
Staging procedures included complete history and phys-
ical examination, laboratory assessments, and diagnostic
bilateral mammogram. Where indicated, ultrasonography of
the breast and abdomen, chest radiograph, and radionu-
clide bone scan were performed. Selected patients received
magnetic resonance imaging (MRI) of the breast, comput-
erized tomography (CT), or positron emission tomography-
computed tomography (PET-CT). Patients were presented
and discussed in an interdisciplinary Tumor Board Meeting,
and a treatment recommendation was generated usually bas-
ed on the guidelines of the National Comprehensive Cancer
Network (NCCN).
Breast conserving surgery (BCS) consisted of wide local
excision or lumpectomy and axillary dissection or sentinel
lymph node biopsy in selected patients. After modiﬁed rad-
ical mastectomy, in selected patients breast reconstruction
with TRAM-ﬂap or latissimus dorsi-ﬂap was performed.
Surgery was followed by chemotherapy and hormonal ther-
apy where indicated. Dependent on the T status, N sta-
tus, hormone receptor status, age (≤35 years versus >35
years), and menopausal status, four cycles of Adriamycin/
Cyclophosphamide (AC) or six cycles of Cyclophospham-
ide/Methotrexate/5-FU (CMF) were prescribed for node-
negative patients, and four cycles of AC followed by four
cyclesof paclitaxelor,alternatively,threecyclesof 5-FU/Epi-
rubicin/Cyclophosphamide(FEC)followedbythreecyclesof
docetaxelfornodepositivepatients.Endocrinetherapyusing
tamoxifen or aromatase inhibitors was prescribed where
indicated. Herceptin was added according to the Her2neu
status and prescribed for at least one year. Triple negative
patients were usually treated with four cycles of AC followed
by four cycles of paclitaxel. In selected patients neoadjuvant
chemotherapy was applied.
Postoperative radiotherapy was performed in all patients
after BCS. A total dose of 50.4Gy in 28 fractions was
prescribed, followed by a boost of 10Gy in 5 fractions in
all patients younger than 50 years. Postmastectomy radio-
therapy of the chest wall was given in patients with at
least one positive locoregional lymph node. The prescribed
dose was 50Gy in 25 fractions. Usually three-dimensional
conformal radiotherapy (3D-CRT) using opposed tangential
beam was applied for the treatment of the whole breast
or the chest wall. In selected patients, intensity modulated
radiotherapy (IMRT) was used to reduce the dose volume of
the heart and lung [38].
Follow-up examinations were scheduled every three
months in the ﬁrst year, then every six months for 4 years.
BreastcancerwasclassiﬁedaccordingtotheInternational
Union Against Cancer (UICC), with group clinical and path-
ological staging according to the American Joint Committee
on Cancer (AJCC, 6th edition).
Data were entered into a computerized database (MS
Access2010)andanalysedusingastatisticalsoftwarepackage
(SPSS 19).
2.1. Immunohistochemistry. Sections with a thickness of four
µmw e r ec u tf r o mp a r a ﬃn blocks and used for immunohis-
tochemical staining using the iVIEW DAB detection kit on
BenchMark autostainer (Ventana, Tucson, AZ, USA). The
clones of antibodies SP1, 1E2, and 4B5 were used to evaluate
the ER-a, PR, and Her2neu status. The Allred scoring system
was used to assess the ER and PR status [39]. In summary,
a total Allred score was obtained by the summation of
proportion score (PS) and intensity score (IS). PS is assigned
depending on the proportion of positive cells (0 = none; 1
<1%; 2 = 1% -<1/10; 3 = 1/10 -<1/3; 4 = 1/3 -<2/3; 5 ≥2/3),
IS (0 = none; 1 = weak; 2 = intermediate; 3 = strong). A total
score of 2 or more was considered as positive; scores 0 and 1
were considered negative.
The American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) guideline recommen-
dations were used to evaluate the Her2neu status [40].
Brieﬂy, score 0 indicates no staining in invasive tumor cells.
Score +1 indicates weak incomplete membrane staining in
any proportion of invasive tumor cells or weak complete
membrane staining in <10% of cells. Score +2 indicates
complete membrane staining in nonuniform or weak but
with obvious circumferential distribution in ≥10% of cells,
or intense complete membrane staining in ≤30% of tumor
cells. Score +3 indicates uniform intense membrane staining
of >30% of invasive tumor cells. Scores 0 and +1 were con-
sidered negative; +2 equivocal; and +3 positive.
Gene expression proﬁling studies have shown that im-
munohistochemistry of paraﬃns e c t i o n si sar e l i a b l es u r r o -
gate for molecular classiﬁcation of invasive breast cancers
[41–46]. Based on this ﬁnding, patients of this study were
categorized as follows: luminal A (ER+, PR+, Her2neu−),
luminal B (ER+ and/or PR+, Her2neu+), Her2neu overex-
pressing (ER−,P R −, Her2neu+), and triple negative (ER−,
PR−,H e r 2 n e u −).
2.2. Statistical Analysis. The Z-test was used to test for statis-
tically signiﬁcant diﬀerent proportions concerning disease-
and treatment-related factors of patients ≤40 years versus
>40 years.
The locoregional failure-free survival was estimated
using the Kaplan-Meier method, and patient groups were
compared using the log rank test. The locoregional failure-
free survival was deﬁned as the time between diagnosis and
locoregional failure or death of any cause. Patients who have
not experienced a locoregional failure were censored at the
time of their last follow-up. The simultaneous relationship
of multiple prognostic factors to locoregional failure wasJournal of Oncology 3
Table 1: Comparison of clinical and pathological characteristics of patients ≤40 years and >40 years of age at diagnosis.
Characteristic
Age (years)
P value ≤40 >40
n % n %
Body mass index
<25 14 25.5 13 8.2 ≤0.05
25–29 14 25.5 36 22.8 n.s.
≥30 14 25.5 69 43.7 ≤0.05
Unknown 13 23.6 40 25.3 n.s.
Menopausal status
Premenopausal 54 98.2 75 47.5 ≤0.05
Postmenopausal 1 1.8 86 52.5 ≤0.05
Family history
No cancers in blood relatives 23 41.8 57 36.1 n.s.
Other than breast cancer in at least one blood
relative 1 1.8 4 2.5 n.s.
Other than breast cancer in at least one ﬁrst
degree relative 6 10.9 8 5.1 n.s.
Breast cancer or ovarian cancer in at least one
blood relative 4 7.3 13 8.2 n.s.
Breast cancer or ovarian cancer in at least one ﬁrst
degree relative 2 3.6 19 12.0 n.s.
Unknown 19 34.5 57 36.1 n.s.
Histology
Invasive ductal 49 89.1 143 90.5 n.s.
Invasive lobular 2 3.6 12 7.6 n.s.
DCIS 3 5.5 3 1.9 n.s.
LCIS 1 1.8 0 0 n.a.
Ts t a g e
Tis 4 7.3 3 1.9 n.s.
T0 1 1.8 0 0.0 n.a.
T1 16 29.1 55 34.8 n.s.
T2 22 40.0 59 37.3 n.s.
T3 4 7.3 27 17.1 n.s.
T4 6 10.9 10 6.3 n.s.
Tx 2 3.6 4 2.5 n.s.
Ns t a g e
N0 18 32.7 59 37.3 n.s.
N1 17 30.9 46 29.1 n.s.
N2 11 20.0 23 14.6 n.s.
N3 6 10.9 26 16.5 n.s.
Nx 3 5.5 4 2.5 n.s.
Stage
0 4 7.3 3 1.9 n.s.
I 6 10.9 35 22.2 n.s.
II 19 34.5 56 35.4 n.s.
III 23 41.8 59 37.3 n.s.
Unknown 3 5.5 5 3.2 n.s.4 Journal of Oncology
Table 1: Continued.
Characteristic
Age (years)
P value ≤40 >40
n % n %
Grading
G1 2 3.6 14 8.9 n.s.
G2 17 30.9 47 29.7 n.s.
G3 22 40.0 71 44.9 n.s.
Gx 14 25.5 26 16.5 n.s.
Lymphovascular invasion (LV)
LV0 17 30.9 50 31.6 n.s.
LV1 15 27.3 53 33.5 n.s.
Unknown 23 41.8 55 34.8 n.s.
Type of surgery
Breast conserving surgery 22 40.0 70 44.3 n.s.
Mastectomy 33 60.0 88 55.7 n.s.
Neoadjuvant chemotherapy
No 46 83.6 137 86.7 n.s.
Yes 9 16.4 21 13.3 n.s.
Residual tumor (R) status
R0 41 74.5 122 77.2 n.s.
R1 3 5.5 12 7.6 n.s.
Unknown 11 20.0 24 15.2 n.s.
Estrogen receptor (ER) status
ER negative 17 30.9 43 27.2 n.s.
ER positive 33 60.0 106 67.1 n.s.
Unknown 5 9.1 9 5.7 n.s.
Progesterone receptor (PR) status
PR negative 23 41.8 52 32.9 n.s.
PR positive 27 49.1 97 61.4 n.s.
Unknown 5 9.1 9 5.7 n.s.
Her2neu status
Her2neu negative 33 60.0 115 72.8 n.s.
Her2neu positive 12 21.8 29 18.4 n.s.
Unknown 10 18.2 14 8.9 n.s.
Tumor subtype
Luminal A 20 36.4 94 59.5 ≤0.05
Luminal B 9 16.4 17 10.8 n.s.
Her2 overexpressing 3 5.5 12 7.6 n.s.
Triple negative 14 25.5 21 13.3 ≤0.05
Unknown 9 16.4 14 8.9 n.s.
assessed using Cox’s proportional hazard regression analysis.
The regression coeﬃcients were estimated by the maximum
likelihood method, and model selection was performed by
a stepwise strategy using the likelihood ratio test. A 5%
signiﬁcance level was used and all tests are two-sided. No
correction for multiple testing was used.Journal of Oncology 5
Table 2: Results of the Kaplan-Meier analysis.
Factor n
2-year locoregional
failure-free
survival
95% CI P value
Age 0.005
Age ≤40 54 0.86 0.75–0.98
Age >40 158 0.98 0.95–1.00
Menopausal status 0.52
Premenopausal 129 0.99 0.97–1.00
Postmenopausal 84 0.97 0.91–1.00
BMI 0.31
BMI <30 72 0.95 0.88–1.00
BMI ≥30 83 0.97 0.92–1.00
Ts t a g e 0.03
Tis, T0–2 159 0.98 0.95–1.00
T3-4 47 0.89 0.78–1.00
Ns t a g e 0.13
N0 77 1.00 1.00-1.00
N+ 128 0.94 0.88–1.00
Grading 0.27
G1-2 80 1.00 1.00-1.00
G3 93 0.93 0.86–1.00
Tumor subtype 0.03
Luminal A 75 0.91 0.83–0.99
Others∗ 114 0.99 0.97–1.00
Lymphovascular status 0.02
LV0 67 1.00 1.00-1.00
LV1 68 0.90 0.79–1.00
Type of surgery 0.59
Mastectomy 121 0.96 0.91–1.00
BCS 91 0.97 0.92–1.00
Residual tumor status 0.56
R0 163 0.97 0.93–1.00
R1 15 1.00 1.00-1.00
Abbreviations. BMI: body mass index; ∗: luminal B, Her2 overexpressing, or triple negative; BCS: breast conserving surgery; CI: conﬁdence interval.
3. Results
The proportion of patients ≤40 years of all breast cancer
patients who consulted Saad Specialist Hospital was 22.6%,
which is very much in accordance to the proportion of
breast cancer patients ≤40 years published by the Cancer
Incidence and Survival Report Saudi Arabia 2007 of 25.1%
[6]. Two hundred and thirteen of all breast cancer patients
met the eligibility criteria of this study and were analysed. Of
those, 158 patients were >40 years of age at diagnosis and 55
patients ≤40 years.
The patient and treatment characteristics are demon-
strated in Table 1. The median follow-up time of the
censored patients was 22 months (mean 28 months, range
3–92 months).
Patients of ≤40 years at diagnosis exhibited statistically
signiﬁcantly less frequently the tumor type luminal A, and
statistically signiﬁcantly more frequently the tumor type
triple negative compared to patients >40 years (Table 1). In
addition, the body mass index (BMI) and the menopausal
status were signiﬁcantly diﬀerent in the two age groups
(Table 1). The mean BMI (standard deviation) of all patients
was 31.1 (6.0), of patients ≤40 years 28.3 (5.2), and for
patients >40 years 32.1 (6.0).
On univariate analysis, the age (≤40 versus >40 years), T
stage(Tis,T0–2versusT3-4),moleculartumortype(luminal6 Journal of Oncology
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Figure 1: Locoregional failure-free survival of breast cancer pa-
tients ≤40 years versus >40 years of age at diagnosis.
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Figure 2: Locoregional failure-free survival of breast cancer pa-
tients with luminal A type of tumor versus luminal B, Her2neu
overexpression, or triple negative.
AversusluminalB,Her2neuoverexpression,triplenegative),
andlymphovascularstatus(LV0versusLV1)hadasigniﬁcant
impact on the locoregional failure-free survival (Table 2,
Figures 1 and 2). The N status (N0 versus N+) showed
a statistical trend of an association with the locoregional
failure-free survival (P = 0.13). On multivariate analysis, the
age and T stage remained statistically signiﬁcant (Table 3).
Table 3: Results of Cox proportional hazards regression analysis.
Variable P value Estimated relative
hazard
95% CI for relative
hazard
Age 0.01 0.13 0.03–0.66
T stage 0.05 4.06 1.01–16.3
4. Discussion
InSaudiArabia,theproportionofbreastcancerpatients ≤40
years of age at diagnosis is about three times larger than
generally reported in the West (25.1% versus 3.7%–7.5%).
According to the US Census Bureau [47], the proportion
of females ≤40 years of the Saudi Arabian population
is only 1.5 times larger than that of the US population
(80.4% versus 52.2%; year 2010), suggesting that the larger
proportion of breast cancer patients ≤40 years in Saudi
Arabia may not be fully explained by the diﬀerent age
structures of the two populations. This observation and also
the fact that some studies performed in Asia and Africa
did not ﬁnd a diﬀerent prognosis of younger breast cancer
patients compared to the older counterparts [48, 49]s u g g e s t
that regional diﬀerences may exist concerning the biology
and prognosis of young breast cancer patients. Detailed
clinicopathological and prognostic data are scarce in Saudi
Arabia and the Middle East.
Our data show that young age is an independent negative
prognosticfactorforthelocoregionalcontrolofbreastcancer
patients in Saudi Arabia. The same ﬁnding has been reported
by another retrospective single-institutional study in Saudi
Arabia [50]. Our ﬁndings are compatible with the notion
that breast cancer arising in a younger host is a unique entity
characterized not only by adverse prognostic features, but
also by a diverse underlying biology against which novel
therapeutics should be targeted [1, 31]. Several current con-
sensus guidelines have included age ≤3 5y e a r sa sa na b s o l u t e
indication for adjuvant systemic chemotherapy irrespective
of other tumor characteristics [32–35]. The observation of
a higher locoregional recurrence rate after BCS compared
to mastectomy in patients ≤35 years of age in some studies
[20, 21, 28, 51–56] raised the question about the optimal
surgical approach of this patient group. However, a recently
publishedlargepopulation-basedanalysisconsistingof1,453
early breast cancer patients ≤40 years showed that the 10-
year overall survival was not impaired after BCS compared
to mastectomy [57]. In line with this observation, no dif-
ference of the two-year locoregional failure-free survival was
detected in our study after BCS or mastectomy (P = 0.59). A
pooled analysis of four EORTC randomized controlled trials
revealed that tumor size, nodal status, and molecular tumor
subtype were independent prognostic factors for overall
survival of the subgroup of young breast cancer patients
[58].The authorsconcluded thatfuturetreatmentguidelines
concerning young breast cancer patients should be reﬁned
based upon tumor characteristics, probably derived from
microarray driven translational research projects, and not
based upon age alone [59–61]. In our study, the molecular
tumor subtype had a prognostic relevance for all patients onJournal of Oncology 7
univariate analysis, but lost its signiﬁcance on multivariate
analysis.
Breast cancer in young women is probably the result of
a complex interaction between genetic, environmental, and
nongenetic patient related factors [24, 25, 27, 31, 62–68].
However, no signiﬁcant diﬀerence of the family history was
found between breast cancer patients ≤40 years and >40
years in our study. A striking diﬀerence to representative
data from North America or Europe was the signiﬁcantly
higher BMI of our study patients. The mean BMI (stan-
dard deviation) of our study population was 31.1 (6.0)
compared to 24.8 (4.4) in North America [69]) and 25.5
(4.5) in Europe [70]. A closer look revealed that the main
diﬀerence was conﬁned to the subgroup of young patients.
In our study, the proportion of patients ≤40 years with
aB M Io f≤25, 25–30, and >30 was about 33% for each
category, whereas in the western studies the corresponding
proportions ranged from 57.0%–73.2%; 19.4%–27.5%, and
12.1%–17.1%, respectively [71–75]. The diﬀerences of the
BMI of older patients compared to the West were much
smaller (our study: 58.5%, 30.5%, and 11.0%; western
studies: 41.6%–52.9%, 28.7–37.5%, and 11.5%–20.9% [74,
75]).
Studies have shown that the BMI is associated with poor
prognosis in both premenopausal [72–74, 76, 77] and post-
menopausal patients [74–80]. In addition, the BMI has been
shown to be associated with an increased breast cancer risk
in postmenopausal women [69, 70, 81]. In premenopausal
women, a protective or no eﬀect of the BMI on the breast
cancer risk has been observed [70, 71, 82–86]. In contrast,
several studies considering multiple surrogate markers for
obesity have also reported an association of obesity with an
increased risk to develop breast cancer in premenopausal
women [69, 87, 88]. Although the association between
body weight and breast cancer appears to be complex, it
represents an interesting factor to be evaluated in future
studies concerning breast cancer in Saudi Arabia.
5. Conclusions
Patients ≤40 years exhibited more often triple negative
and less frequently luminal A tumors compared to patients
>40 years. However, multivariate analysis revealed age ≤40
years as an independent adverse prognostic factor for the
locoregional failure-free survival of breast cancer patients in
Saudi Arabia.
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